Portage Biotech Inc. announced new appointments to its management team and Board of Directors. Brian Wiley, who has served in leadership roles at multiple pharmaceutical companies including Celgene and Millennium Pharmaceuticals, will join Portage's executive team as Chief Business Officer and Joseph Ciavarella, who joined the company in 2020 as a financial consultant, now joins as Chief Accounting Officer. In addition, Jim Mellon, Linda M. Kozick and Mark Simon will join the company's Board of Directors.

Mr. Mellon was one of the founders of Portage. The new members will assume Board of Director responsibilities effective immediately while current members Kamlesh Shah and Declan Doogan will be retiring. Brian Wiley has nearly 30 years of experience in the biopharmaceutical industry, with over 25 years dedicated to oncology.

His experience includes licensing deals, collaborations, M&A, both public and private financings, and multiple product launches in oncology. As Chief Accounting Officer, Joseph Ciavarella will direct all financial reporting activities at Portage. Prior to joining the company, Mr. Ciavarella has most recently provided senior financial consulting services to middle market companies.

He has also been Chief Financial Officer for several public and private corporations across multiple industries, from telecom and financial services to health care and biotech, with deep experience with start-ups and restructurings. Further info on new members of Portage's Board of Directors: Jim Mellon is an author, entrepreneur and investor. He was one of the founders of Portage Biotech and is the co-author of five books, all written with a view toward identifying emerging thematic trends leading to investment opportunities.

He is a founder and Executive Director of Agronomics Limited an investment vehicle for cellular agriculture and cultivated meat. Linda M. Kozickhas more than 25 years of experience in the biopharmaceutical industry, including 15 years of strategic commercial leadership in oncology with a focus in immuno-oncology. Prior to retiring she held leadership positions at Bristol Myers Squibb and was instrumental to Obdivo and Yervoy product management and portfolio strategy.

Mark Simon has over 30 years advising experience for biotech and pharma companies as an investment banker and research analyst. He is the Co-founder and an advisor of Torreya Capital, LLC, a global investment bank serving companies in the life sciences industry.